Researcher

GENE

Genomic screening of the Embryo for Novel targets in the tumor Endothelium

 

Contact

e.huijbers@vumc.nl

ORCID researcher ID

0000-0002-7742-9893

Marie Curie Actions -

Intra-European Fellowship

 

FP7-PEOPLE-2012-IEF

 

 

Dr. Elisabeth J.M. Huijbers

CURRENT POSITION

Postdoctoral fellow

Department of Medical Oncology, VU University Medical Center,

Cancer Center Amsterdam, The Netherlands

PREVIOUS POSITIONS

EU Marie Curie postdoctoral fellow (GENE, FP7-PEOPLE-2012-IEF)

Department of Medical Oncology, VU University Medical Center,

Cancer Center Amsterdam, The Netherlands

 

Postdoctoral fellow (May 2012 - April 2013)

Department of Medical Biochemistry and Microbiology,

Uppsala University, Sweden

Project: Development of a cancer vaccine targeting tumor blood vessels

Research group of Associate Professor Dr. Anna-Karin

 

EDUCATION

PhD degree (11 May 2012): Medical Faculty, Uppsala University, Sweden

PhD thesis: Development of a cancer vaccine targeting tumor blood vessels

Supervisor: Associate Professor Dr. Anna-Karin Olsson

 

Licentiate degree (4 March 2010): Medical Faculty, Uppsala University, Sweden, 2010-03-04

Licentiate thesis: Targeting tumor vessels by therapeutic vaccination

Supervisor: Associate Professor Dr. Ann-Karin Olsson

 

Master of pharmaceutical sciences degree (23 November 2005):

Faculty of Science, Utrecht University, The Netherlands, 2005-11-23

 

‘Doctoraal’* degree in pharmaceutical sciences (year 2003):

Faculty of Science, Utrecht University, The Netherlands, 2003

 

*equivalent to bachelor degree, but 4-year education

 

RESEARCH EXPERIENCE

Research Project (September 2007 - February 2008):

Development of a cancer vaccine targeting tumor blood vessels

Department of Immunology, Genetics and Pathology, Uppsala University, Sweden

Supervisor: Associate Professor Dr. Anna-Karin Olsson

 

Internship (August 2005; 4 weeks): literature search about methadone programs and writing of a grant application for funding of an inter-disciplinary education program

College of Pharmacy and Nutrition, University of Saskatchewan, Canada

Supervisor: Professor Dr. Roy Dobson

 

Master thesis (August 2002 - February 2003): Qualitative and quantitative analysis of drug efflux-proteins in different cell lines

Department of Pharmacy, Uppsala University, Sweden

Research group of Professor Dr. Per Artursson, supervisor: Dr. Ann-Cathrin Engwall

 

WORK EXPERIENCE

Community pharmacist and store manager (January 2006 - July 2007): community pharmacist in Zaltbommel and manager of a small pharmacy store in Gameren

Employer: Marjolein Menheere, Stadsapotheek Zaltbommel B.V., Zaltbommel, The Netherlands

 

PUBLICATIONS

Saupe F, Huijbers EJM, Hein T, Femel J, Cedervall J, Olsson AK, Hellman L. Vaccines targeting self-antigens: mechanisms and efficacy-determining parameters. (2015) FASEB J. [Epub ahead of print]

 

Huijbers EJM, Paulis Y, Soetekouw P, Tjan-Heijnen P, Griffioen AW. CD44 determines tumor cell aggressiveness. (2015) Oncotarget

[Epub ahead of print]

 

van Beijnum JR, Nowak-Sliwinska P, Huijbers EJM, Thijssen VL, Griffioen AW. The great escape; the hallmarks of resistance to antiangiogenic

therapy. (2015) Pharmacol Rev. 67:441-61

 

Wentink, MQ, Huijbers EJM, De Gruijl, TD, Verheul, HM, Olsson AK, Griffioen AW. Vaccination approach to angiostatic therapy. (2015) BBA Cancer, 1855:155-171

 

Femel J, Huijbers EJM, Saupe F, Cedervall J, Zhang L, Roswall P, Larsson E, Olofsson H, Pietras K, Dimberg A, Hellman L, Olsson AK. Therapeutic vaccination against fibornectin ED-A attenuates progression of metastatic breast cancer. (2014) Oncotarget 5:12418-27

 

Huijbers EJM, Ringvall M, Femel J, Kalamajski S, Lukinius A, Åbrink M, Hellman L. and Olsson AK. Vaccination against the extra domain-B of fibronectin as a novel tumor therapy. (2010) FASEB J. 24: 4535-44.

 

Huijbers EJM, Femel J, Andersson K, Björkelund H, Hellman L. and Olsson AK. The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund’s in a cancer vaccine targeting ED-B – a prerequisite for clinical development. (2012) Vaccine 30: 225-230.

 

Ringvall M, Huijbers EJM, Ahooghalandari P, Alekseeva L, Andronova T, Olsson AK, Hellman L. Identification of potent biodegradable adjuvants that efficiently break self- tolerance - a key issue in the development of therapeutic vaccines. (2009) Vaccine 28: 48-52.

 

Huijbers EJM, Baars JW, Schutte PF, Schellens JH, Beijnen JH. Propofol extravasation in a breast cancer patient. (2008) J Oncol Pharm Pract. 14: 195-8.

 

Boer S de*, Dingemans JA*, Huijbers EJM*, Zych TR*, Beijnen JH. De keerzijde van succes. Late cardiotoxiciteit bij antracyclinegebruik (The downside of succes. Late cardiotoxicity after anthracycline use). (2006) Pharmaceutisch Weekblad (Dutch Pharmaceutical Journal) 37: 1154-1157 *Equal contribution.

 

Huijbers EJM, De ontwikkeling van een vaccin dat aangrijpt op de tumorangiogenese (Development of a vaccine targeting tumor angiogenesis). (2012) Pharmaceutisch Weekblad Wetenschappelijk Platform 6:a1224

 

LINKS

http://www.diva-portal.org/smash/get/diva2:512413/FULLTEXT01.pdf

http://www.ncbi.nlm.nih.gov/pubmed/18753182

 

 

Disclaimer: E. Huijbers, updated 15 October 2014